US healthcare reform: painting the future for the pharma industry
This article was originally published in Scrip
Executive Summary
The main take-away from the landmark healthcare reform in the US is that drug makers – who saw an advantage early on with working with the Obama administration in order to limit the financial hit – have come away with a bill that is broadly favourable to them. The positives include expanded insurance coverage that would increase the usage of brand-name prescription drugs.